This research aims to evaluate the efficacy of personalised transcranial alternating current stimulation (tACS) as a therapeutic approach for Major Depressive Disorder (MDD). By using electroencephalography (EEG) to measure individual brain activity, we will tailor tACS treatments to the frontal brain regions of participants. The study is divided into two parts: Part A is an open-label trial with 10 participants receiving active treatment. Part B involves 50 participants in a randomized, double-blind, parallel-group, sham-controlled trial, comparing active tACS with a placebo.

We hypothesise that personalised theta stimulation sessions will modulate theta activity at rest and during cognitive tasks and alleviate self-reported mood symptoms. We expect these effects to be more pronounced in the active treatment group compared to the sham group in Part B. The findings could advance personalised neuromodulation therapies for MDD, potentially leading to more effective and tailored treatments.